Copyright
©The Author(s) 2018. Published by Baishideng Publishing Group Inc. All rights reserved.
Serum anti-Helicobacter pylori antibody titer and its association with gastric nodularity, atrophy, and age: A cross-sectional study
Osamu Toyoshima, Toshihiro Nishizawa, Kosuke Sakitani, Tadahiro Yamakawa, Yoshiyuki Takahashi, Nobutake Yamamichi, Keisuke Hata, Yasuyuki Seto, Kazuhiko Koike, Hidenobu Watanabe, Hidekazu Suzuki
Osamu Toyoshima, Toshihiro Nishizawa, Kosuke Sakitani, Tadahiro Yamakawa, Yoshiyuki Takahashi, Gastroenterology, Toyoshima Endoscopy Clinic, Tokyo 157-0066, Japan
Nobutake Yamamichi, Kazuhiko Koike, Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Tokyo 113-8655, Japan
Keisuke Hata, Department of Surgical Oncology, Graduate School of Medicine, The University of Tokyo, Tokyo 113-8655, Japan
Yasuyuki Seto, Department of Gastrointestinal Surgery, Graduate School of Medicine, The University of Tokyo, Tokyo 113-8655, Japan
Hidenobu Watanabe, Pathology and Cytology Laboratory Japan, Tokyo 166-0003, Japan
Hidekazu Suzuki, Medical Education Center, Keio University School of Medicine, Tokyo 160-8582, Japan
Author contributions: All authors were involved in designing the study; Toyoshima O, Nishizawa T, Sakitani K, and Suzuki H prepared the manuscript; Toyoshima O was involved with statistical analysis.
Institutional review board statement: This retrospective study was approved by the Ethical Review Committee of Hattori Clinic on September 7, 2017.
Informed consent statement: Written informed consent was obtained from all participants.
Conflict-of-interest statement: During the last five years, Yamamichi N received funds for the research from Denka Seiken Co., Ltd.
Data sharing statement: No additional data are available.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Osamu Toyoshima, MD, Director, Gastroenterology, Toyoshima Endoscopy Clinic, 6-17-5 Seijo, Setagaya-ku, Tokyo 157-0066, Japan.
t@ichou.com
Telephone: +81-3-54299555 Fax: +81-3-54299511
Received: July 17, 2018
Peer-review started: July 17, 2018
First decision: July 31, 2018
Revised: August 2, 2018
Accepted: August 24, 2018
Article in press: August 24, 2018
Published online: September 21, 2018
Processing time: 65 Days and 11.3 Hours
ARTICLE HIGHLIGHTS
Research background
Serum anti-Helicobacter pylori (H. pylori) antibody titer and endoscopic findings are associated with the risk of gastric cancer.
Research motivation
Few studies have reported on the relationship between the serum antibody titer and endoscopic findings.
Research objectives
To clarify the role of serum anti-H. pylori antibody titers in gastric cancer.
Research methods
A cross-sectional study was conducted to investigate the effect of patients’ baseline characteristics and endoscopic findings on their serum antibody titers. We excluded patients with a history of eradication therapy.
Research results
Gastric nodularity, atrophy, and age 40-59 years (vs age ≥ 60 years) were correlated with a high serum antibody titer in H. pylori-infected patients.
Research conclusions
Serum antibody titer reflects gastric mucosal inflammation
Research perspective
In the future, population-based research is expected.
